For example, Patritumabderuxtecan is a monotherapy drug under phase 1 clinical trial; it is an anti-HER3 antibody–drug conjugate targeting mutated EGFR and NSCLC that has progressed after tyrosine kinase inhibitors (TKI) showing an objective response rate (ORR) of 39%. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.